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Abstract
The objectives of this study were to evaluate the effects of tanshinones from a Chinese herb Salvia Miltiorrhiza on the
growth of breast cancer cells, and to elucidate cellular and molecular mechanisms of action. Tanshinones showed the dose-
dependent effect on the growth inhibition of breast cancer cells in vitro, with tanshinone I (T1) the most potent agent. T1
was also the only tanshinone to have potent activity in inhibiting the growth of the triple-negative breast cancer cell line
MDA-MB231. T1 caused cell cycle arrests of both estrogen-dependent and estrogen-independent cell lines associated with
alterations of cyclinD, CDK4 and cyclinB, and induced breast cancer cell apoptosis associated with upregulation of c-PARP
and downregulation of survivin and Aurora A. Among these associated biomarkers, Aurora A showed the most consistent
pattern with the anti-growth activity of tanshinones. Overexpression of Aurora A was also verified in breast tumors. The
gene function assay showed that knockdown of Aurora A by siRNA dramatically reduced the growth-inhibition and
apoptosis-induction activities of T1, suggesting Aurora A as an important functional target of T1 action. On the other hand,
tanshinones had much less adverse effects on normal mammary epithelial cells. Epigenetic mechanism studies showed that
overexpression of Aurora A gene in breast cancer cells was not regulated by gene promoter DNA methylation, but by
histone acetylation. T1 treatment significantly reduced acetylation levels of histone H3 associated with Aurora A gene. Our
results supported the potent activity of T1 in inhibiting the growth of breast cancer cells in vitro in part by downregulation
of Aurora A gene function. Our previous studies also demonstrated that T1 had potent anti-angiogenesis activity and
minimal side effects in vivo. Altogether, this study warrants further investigation to develop T1 as an effective and safe
agent for the therapy and prevention of breast cancer.
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Introduction
Breast cancer is the most common form of cancer in women
and the leading cause of cancer death in American women with
over 207,090 new cases of invasive breast cancer in women and
about 39,840 deaths from breast cancer in 2010 [1]. Current
therapies for breast cancer usually have variable effectiveness with
high toxicity to normal tissues, and breast tumors often develop
metastasis and drug resistance. Therefore, searching for effective
regimens with minimal side effects remains the top priority in
breast cancer research.
Danshen (Salvia miltiorrhiza Bunge) has been widely used in
traditional Chinese medicine practice for centuries in the
treatment of coronary artery disease and cerebrovascular diseases
with minimal side effects. Cryptotanshinone (CT), tanshinone IIA
(T2A) and tanshinone I (T1) are three major diterpene compounds
of tanshinones in Danshen. In addition to their functions in
cardiovascular systems, tanshinones have been recently shown to
possess some activities against human cancer cells. CT inhibited
the growth of hepatocarcinoma cells [2] in vitro via cell cycle
arrest at S phase and the growth of gastric and hepatocellular
cancer cells. T2A inhibited the growth of breast cancer [3,4],
nasopharyngeal carcinoma [5], glioma [6], leukemia [7] and
hepatocellular carcinoma [8,9] cells in vitro by induction of
apoptosis [5,8]. T2A also inhibited invasion of lung cancer cells in
vitro [10]. T1 inhibited the growth of leukemia [11], lung [12] and
breast cancer [13,14] in vitro in part via induction of apoptosis.
However, the relative activity of tanshinones against breast cancer
is unclear, and their functional targets and molecular mechanisms
remain elusive.
The objectives of this study were to evaluate the activity of
tanshinones in inhibiting the growth of breast cancer cells, to
identify functional targets of tanshinones, and to understand the
epigenetic mechanisms by which tanshinones regulate the
expression of functional targets.
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Effects of Tanshinones on Cell Growth of Breast Cancer
Cell Lines and HMEC
As shown in Fig. 1, tanshinones inhibited the growth of breast
cancer cells in both dose- and cell line-dependent manners. CT
inhibited cell growth of different breast cancer cell lines with IC50
between 5–50mM; among four cell lines, MDA-MB453 was the
most sensitive one with IC50 around 5mM, while MDA-MB231
was the least sensitive one with IC50 around 50mM (Fig. 1A). T2A
inhibited the growth of breast cancer cell lines with MDA-MB-453
the most sensitive one (IC50=3.5mM) and MDA-MB-231 the least
sensitive one (IC50 .50mM) (Fig. 1B). On the other hand, T1
showed the potent activity in inhibiting the growth of all breast
cancer cell lines with IC509s between 4–9mM (Fig. 1C). Generally,
among three tanshinones, CT showed less activity, T1 and T2A
showed similar activities in inhibiting the growth of MDA-MB453
and SKBR3 cell lines, but T1 was more potent than T2A in
inhibiting the growth of MCF-7 and especially MDA-MB231 cell
lines. On the other hand, tanshinones showed much less
cytotoxicity on normal mammary epithelial cells (HMEC)
(Fig. 1D). The results suggest that tanshinones may have potent
anti-growth effects on breast cancer cells, but limited adverse effect
on normal cells.
Effects of T1 on Cell Cycle Progression of Breast Cancer
Cells and Modulation of Related Molecular Markers
Since T1 showed the potent effect on all breast cancer cell lines,
in the following studies, we mainly focused on T1 to determine its
cellular and molecular mechanisms in both estrogen-dependent
MCF-7 and estrogen independent MDA-MB231 cell lines. The
cell cycle analysis data showed that T1 caused a G0/G1 phase
arrest in MCF-7 (Fig. 2A, P,0.01) and both S and G2/M phase
arrests in MDA-MB231 (Fig. 2B, P,0.05). The representative
FACS histograms are shown as Fig. S1.
In order to examine molecular alterations associated with cell
cycle arrest, we determined protein expression levels of several cell
cycle related markers. T1 treatment significantly down-regulated
cyclin D, CDK4 and cyclin B protein levels in both MCF-7
(Fig. 2C and 2D) and MDA-MB231 cell lines (Fig. 2C and 2E). T1
also significantly downregulated protein levels of cdc2 and its
active form, phosphorylated cdc2 (p-cdc2) in MCF-7 cell line
(Fig. 2C and 2D) and p-cdc2 level in MDA-MB231 cell line
(Fig. 2C and 2E).
Figure 1. The dose-dependent effects of CT (A), T2A (B) and T1 (C) on the growth of human breast cancer cell lines (MCF-7, MDA-
MB231, SKBR3 and MDA-MB453) and on normal mammary epithelial cells (HMEC) (D). Values were mean6SEM of at least three
independent experiments, each in triplicates.
doi:10.1371/journal.pone.0033656.g001
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Modulation of Related Molecular Markers
Aside from the disturbance of cell cycle, T1 was also found to
induce apoptosis in breast cancer cells. T1 treatment increased the
proportion of Sub-G0 cells, a parameter of apoptosis, in both
MCF-7 and MDA-MB231 cell lines in a dose-dependent manner
(Fig. 3A). T1 at 3 and 4mM significantly increased the proportion
of Sub-G0 MCF-7 cells to 8% (1.3 folds, P,0.05) and 12% (2.0
folds, P,0.005), respectively, compared with 6% in the control
(Fig. 3A). Similarly, T1 (3 and 4mM) increased the proportion of
Sub-G0 MDA-MB231 cells to 3% (2.0 folds, P,0.05) and 3.5%
(2.3 folds, P,0.01), respectively, compared with 1.5% in the
control (Fig. 3A).
Consistent with cellular results, T1 treatment significantly
increased the protein level of an important apoptosis related
protein marker, cleaved PARP (c-PARP) in both MCF-7 and
MDA-MB231 cells (Fig. 3B and 3C, P at least ,0.05). Other
apoptosis related markers, bcl-2 and bax were also examined, and
the results showed that T1 reduced bcl-2 protein levels in both
MCF-7 and MDA-MB231 cell lines, but had no effect on bax
levels (Fig. 3B).
Gene Expression and Protein Levels of Survivin and
Aurora A levels in Human Breast Tumors and Breast
Cancer Cell Lines
In addition to above molecular markers, we further identified
other molecular markers that might be responsive to and
responsible for the T1 activity. In this study, survivin and Aurora
A were investigated as putative targets of T1 mechanism of action,
because these biomarkers were differentially expressed in cancer
cell lines in comparison to normal mammary epithelial cells.
Survivin (Fig. 4C) and Aurora A (Fig. 4D) genes were significantly
upregulated in human breast cancer cell lines by 4–5 folds and 20–
50 folds respectively, compared with that in HMEC. Western blot
analysis confirmed overexpression of survivin and Aurora A
protein levels in breast cancer cell lines (Fig. 4E). We further
compared the expression of survivin and Aurora A genes among
human breast tumors, breast tissues adjacent to breast tumors and
breast tissues from healthy subjects. The results showed that both
survivin and Aurora A genes were extremely low in both normal
breast tissues of healthy women and breast tissues adjacent to
breast tumors of breast cancer patients, but were dramatically
elevated in breast tumor tissues by about 49 (Fig. 4A) and 14 folds
(Fig. 4B), respectively. Due to limited amount of tissues, protein
levels were not measured in human breast tissue samples.
Figure 2. Effects of T1 on Cell Cycle Progression and Protein Levels of Cell Cycle-Related Biomarkers (48h). A and B: Effects of T1 on cell
cycle arrests of estrogen-dependent MCF-7 (A) and estrogen-independent MDA-MB231 (B) cell lines. Data were from at least two independent
experiments, each in duplicates; C: The representative Western blot images showing the effects of T1 on protein levels of cell cycle related biomarkers
cyclinD, CDK4, cdc2, p-cdc2 and cyclinB; D and E: Quantitation of cyclinD, CDK4, cdc2, p-cdc2 and cyclinB protein levels in MCF-7 (D) and MDA-MB231
(E) by densitometry after normalization to b-actin. Values were mean6SEM of at least two independent experiments. Within the panel, the value with
a letter was significantly different from that of the corresponding control, a, p,0.05; b, p,0.01; c, p,0.001.
doi:10.1371/journal.pone.0033656.g002
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Aurora A in Breast Cancer Cells
We further measured the effects of tanshinones on the survivin
and Aurora A protein levels to determine if Aurora A and/or
survivin are/is the functional molecular targets for tanshinones. As
shown in Fig. 5 (A and B), Aurora A protein levels were
downregulated by tanshinones in a dose-dependent manner. It is
very important to note that the Aurora A protein level in SKBR3
cell line, the least sensitive one to T1 treatment, was not
downregulated by T1 at 4mM, but significantly downregulated
by T1 at 8mM, which was consistent with the T1 activity in cell
growth inhibition. Similarly, MDA-MD231 cell line was the least
sensitive one to CT and T2A, and Aurora A protein levels were
not downregulated by CT or T2A treatment, but significantly
downregulated by T1 treatment (at 3 and 4 mM) (Fig. 5A and 5B).
These results strongly support the correlation between cell growth-
inhibition activities of tanshinones and downregulation of Aurora
A protein levels and thus suggest that Aurora A may be an
important functional target of tanshinones. Further experimental
results also showed that Aurora A gene expression, in parallel with
Aurora A protein level, was significantly downregulated by T1
treatment in MCF-7 and MDA-MB231 cell lines (Fig. S2).
On the other hand, despite different sensitivities of breast cancer
cell lines to tanshinones, survivin was universally downregulated
by tanshinones (Fig. 5A and 5C). These results suggest that
survivin may not be the direct molecular target of tanshinones.
The Effect of Aurora A Silencing on T1 Activity
To further determine if Aurora A is a functional target of T1
actions in inhibiting the growth and inducing apoptosis of breast
cancer cells, we used Aurora A specific siRNA to inhibit the
expression of Aurora A in MCF-7 cells and measured the effect of
Aurora A knockdown on T1 activity. The siRNA inhibited Aurora
A gene expression in a dose-dependent manner. To sensitively
evaluate the effect of siRNA on T1 activity, we purposely used
a dose of siRNA that downregulated Aurora A protein level in
Figure 3. Effects of T1 on apoptosis of breast cancer cells and protein levels of apoptosis-related biomarkers (48h). A: Effects of T1 on
the proportion of DNA fragmentation (sub-G0), a marker of apoptosis, in MCF-7 and MDA-MB231 cell lines. Values were mean6SEM of at least two
independent experiments, each in duplicates; B: The representative Western blot images showing the effects of T1 on protein levels of apoptosis
related biomarkers PARP, c-PARP, bcl2 and bax; C: Quantitation of c-PARP protein levels in MCF-7 and MDA-MB231 by densitometry after
normalization to b-actin. The images for quantitation were from at least two independent experiments. Within the panel, the value with a letter was
significantly different from that of the corresponding control, a, p,0.05; b, p,0.01; c, p,0.001.
doi:10.1371/journal.pone.0033656.g003
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cell growth by 45% (Fig. 6B, P,0.001). Aurora A knockdown
reduced T1 activity in inhibiting the growth of MCF-7 cells. T1 at
4mM inhibited the growth of the vector-control MCF-7 cells by
80% (P,0.001), but inhibited the growth of Aurora A-knockdown
MCF-7 cells by 40% (P.0.05) (Fig. 6B), indicating that Aurora A
knockdown (by 46%) reduced the T1 activity by 50% (from 80%
inhibition to 40% inhibition). Additionally, we determined the
effect of Aurora A knockdown on the apoptosis-induction activity
of T1. Aurora A knockdown (by 46%) significantly increased
MCF7 cell apoptosis by 3 folds (Fig. 6C, P,0.001); T1 (4 mM)
significantly induced apoptosis of the control-siRNA MCF-7 cells
by around 5 folds, but it induced apoptosis of the Aurora A-
knockdown cells by 50% only (Fig. 6C). These results suggest
Aurora A as an important functional target of T1 action.
Epigenetic Modifications of Aurora A Expression in Breast
Cancer Cells
We further investigated possible epigenetic mechanism(s) that
might be responsible for Aurora A overexpression in breast cancer
cells and for explaining the T1 activity in downregulating Aurora
A expression associated with growth inhibition of breast cancer
cells. When MCF-7 cells were treated with 5-AZA, a DNA
demethylating regent, Aurora A gene expression was not altered
(Fig. 7A), suggesting that Aurora A gene expression in breast
cancer cells may not be regulated by DNA methylation. The raw
Ct values are listed in Table S2. Further MSP analysis showed that
Aurora A gene DNA promoter had limited degree of methylation
(Fig. S3). Bisulfite-treated DNA sequencing also confirmed that
Aurora A gene promoter was primarily unmethylated (data not
shown).
Figure 4. Expressions of survivin and Aurora A in human breast tissues and breast cancer cells. A and B: Expressions of survivin (A) and
Aurora A (B) genes in normal breast tissues (n=10), normal tissues adjacent to tumors (n=12) and breast tumors (n=14) by real-time RT-PCR; C and
D: Expressions of survivin (C) and Aurora A (D) genes in human breast cancer cell lines (MCF-7, MDA-MB231, SKBR3 and MDA-MB453) and HMEC; E,
Protein levels of survivin and Aurora A in HMEC and human breast cancer cell lines by western blot. Values were mean6SEM. Within the panel, the
value with a letter was significantly different from that of the corresponding control, c, p,0.001.
doi:10.1371/journal.pone.0033656.g004
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sodium butyrate (SB), a histone deacetylase inhibitor, had an
increased level of Aurora A gene expression by 4 folds (Fig. 7A),
suggesting that Aurora A gene expression in breast cancer cells
may be regulated, at least in part, by histone acetylation. The raw
Ct values are listed in Table S2.
We further examined the histone H3 acetylation levels in
HMEC and MCF-7 cells using CHIP Q-PCR assay. Five pairs of
primers (Table S1) were used for detecting possibly altered sites in
the Aurora A promoter region. The locations covered by these
paired primers are shown in Fig. 7E. No obvious changes of
Aurora A H3 histone acetylation were found in the areas where
primer 1, primer 2 or primer 3 amplified. On the other hand, the
areas where primer 4 and primer 5 amplified had increased H3
acetylation levels by 1.8 (P,0.05) and 8.9 (P,0.01) folds,
respectively, in MCF-7 cells (Fig. 7B). The raw Ct values are
listed in Table S2.
Effect of T1 on Alteration of Histone Acetylation
Associated with Aurora A Gene DNA Promoter
We further determined if T1 downregulated Aurora A gene
expression in part via alteration of histone acetylation in Aurora A
gene DNA promoter. T1 treatment significantly decreased H3
acetylation level in primer 4-amplified area by over 40% (P,0.05),
but it didn’t significantly alter H3 acetylation levels in the primer
5-amplified area (Fig. 7C). The results suggest that T1 may
downregulate Aurora A gene expression by reducing acetylation of
H3 associated with the primer 4-amplified area in Aurora A gene
DNA promoter.
We also determined the influence of SB on the T1 activity in
inhibiting MCF-7 cell growth. As shown in Fig. 7D, the presence
of SB (increased histone acetylation and upregulated Aurora A
expression) reduced the growth inhibition activity of T1 by 25%
(P,0.05). This suggests that modulation of histone acetylation is
an important epigenetic mechanism by which T1 down-regulates
the expression and function of Aurora A.
Discussion
In the present study, we evaluated the activity of a group of
natural components, tanshinones (CT, T1 and T2A) from
a Chinese herb Salvia Miltiorrhiza (Danshen) in inhibiting the
growth of human breast cancer cells. Among these compounds,
T1 showed the most potent anti-growth activity against both
estrogen-dependent and estrogen-independent breast cancer cells
Figure 5. Effects of tanshinones on survivin and Aurora A protein levels in breast cancer cells (48 h). A: Representative western blot
images showing survivin and Aurora A protein levels in breast cancer cell lines (MCF-7, MDA-MB231, SKBR3, MDA-MB453) following tanshinone
treatments with b-actin as the loading control; B and C: Quantitation of Aurora A (B) and survivin (C) protein levels by densitometry after
normalization to b-actin. Values were mean6SEM of three independent experiments in duplicates. The images for quantitation were from at least
two independent experiments. Within the panel, the value with a letter was significantly different from that of the corresponding control, a, p,0.05;
b, p,0.01; c, p,0.001.
doi:10.1371/journal.pone.0033656.g005
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tanshinones showed much less adverse effects on the growth of
HMEC. Determination of biomarkers showed that downregula-
tion of Aurora A was correlated to the anti-growth activity of
tanshinones. The gene function assay showed that Aurora A
knockdown by siRNA reduced the anti-growth and pro-apoptotic
activities of T1. Epigenetic mechanism studies showed that
overexpression of Aurora A in breast cancer cells was, at least in
part, modulated by increased acetylation of histone associated with
Aurora A gene promoter, but not altered gene promoter
methylation. Further studies showed that T1 significantly de-
creased histone acetylation level associated with a specific region in
Aurora A gene promoter. Our study provided at the first time, to
the best of our knowledge, the experimental evidence to suggest
T1 as the potent agent in inhibiting the growth of breast cancer
cells and Aurora A as an important functional target for T1 action
via epigenetic mechanism of histone acetylation.
The Aurora kinases are a novel oncogenic family of mitotic
serine/threonine kinases (S/T kinases) that are involved in the
processes of cell division [15]. Up till now, three Aurora kinases, A,
B and C, have been identified in humans [16,17,18]. Among the
three kinases, Aurora kinase A is a key kinase that is important in
chromosomal distribution. Aurora A is localized on duplicated
centrosomes and spindle poles during mitosis and is required for
the timely entry into mitosis and proper formation of a bipolar
mitotic spindle by regulating centrosome maturation, separation,
and microtubule nucleation activity [19]. Aurora A is frequently
overexpressed in a number of human cancers, such as bladder
[20,21], breast [22], colon [17,23], pancreatic [24] and prostate
[25,26,27,28,29] cancers and is recognized as one of the important
molecular targets for cancer therapy [30,31,32].
In the present study, we, at the first time, demonstrated that the
activity of tanshinones in breast cancer cell growth inhibition was
primarily due to downregulation of the expression and function of
Aurora A. Cautions should be noted that we performed the gene
function assay by knocking down Aurora A gene expression only,
but did not perform the Aurora A overexpression assay. This is the
limitation of the current study, and more experiments using
Aurora A overexpression assay to determine if Aurora A
overexpression could rescue prostate cancer cells from apoptosis
induced by T1 would provide another line of important evidence
to suggest tanshinones as a novel group of Aurora A inhibitors.
Our previous studies also showed that T1 also had potent anti-
angiogenesis activity and inhibited the growth of prostate cancer in
vitro and in vivo [33], but with minimal side effect on food intake
and body weight. These results provide important scientific
Figure 6. Effects of Aurora A knockdown on the T1 activities in growth and apoptosis of MCF-7 breast cancer cells. A: Western blot
analysis showing knockdown of Aurora A protein level in MCF-7 cells by Aurora A siRNA; B: Effect of Aurora A knockdown on the growth-inhibition
activity of T1; C: Effect of Aurora A knockdown on the apoptosis-induction activity of T1. Values were mean6SEM of three independent experiments
in duplicates. Within the panel, the value with a letter was significantly different from that of the corresponding control (c, p,0.001), and the values
with a ‘‘*’’ are significantly different (**, P,0.01; ***, P,0.001).
doi:10.1371/journal.pone.0033656.g006
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especially T1 as effective therapeutic agents against breast cancer.
It is becoming widely accepted that epigenetic alterations are
universally present in human malignancies. Epigenetic alterations
of the genome such as DNA promoter methylation and chromatin
remodeling play an important role in tumorigenesis [34,35].
Recent findings also indicate epigenetic modifications as key
factors in breast carcinogenesis, and as important targets for
preventative care and therapeutics because of their potential for
reversal [36,37]. Epigenetic modification has been recognized as
an important mechanism by which a variety of natural bioactive
compounds exert their anti-cancer effect [38,39,40,41]. However,
it has not been reported if epigenetic mechanism is responsible for
the tanshinones’ anti-cancer activity. Our current study provided,
at the first time, the promising evidence to support that histone
acetylation is an important epigenetic mechanism that behinds the
overexpression of Aurora A in breast cancer and governs the
downregulation of Aurora A function by tanshinones. This study
also supports future investigation to understand how histone
acetylation in the primer 4-amplified region of Aurora A gene
promoter significantly modulates Aurora A gene expression.
It is important to note that the triple-negative breast cancer
(TNBC) cell line MDA-MB231 was very sensitive to T1, but not
CT or T2A. TNBC is clinically characterized as more aggressive
and less responsive and more resistant to standard treatment.
Searching for effective strategies for the treatment of TNBC has
become the top priority in breast cancer therapy. Our results
warrant further investigation to determine if T1 may serve as
a novel candidate agent for the management of TNBC.
Identification of T1 as a potent anti-TNBC agent could have
significant impact on developing novel therapeutic strategies for
the treatment of TNBC.
Figure 7. Epigenetic modifications of Aurora A expression by T1 treatment in breast cancer cells. A: Effect of the demethylating agent
59-Azacytine (5-AZA) or the histone deacetylase inhibitor sodium butyrate (SB) treatment on Aurora A gene expression in MCF-7 cells; B: Identification
of histone H3 acetylation level of DNA promoter areas in Aurora A gene that are associated with overexpression of Aurora A gene in MCF-7 cells by
CHIP; C: Effects of T1 treatment (3 mM) on acetylation levels of histone 3 of Aurora A gene by CHIP; D: Effects of SB (1 mM) treatment on the activity of
T1 in inhibiting the growth of MCF-7 cells; E: Scheme showing the CHIP primer locations for Aurora A gene. Values were mean6SEM of three
independent experiments in triplicates. Within the panel, the value with a letter is significantly different from that of the corresponding control (a,
p,0.05; b, p,0.01), and the values with a ‘‘*’’ are significantly different (*, P,0.05).
doi:10.1371/journal.pone.0033656.g007
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cancer cell lines at the IC50 doses of 4–9mM (Figure 1). Previous
studies have indicated that the blood levels of tanshinones after
oral administration could reach the high nM range [42,43,44,45].
This may raise the concern if tanshinones may have significant
activity in vivo. On the other hand, our previous animal studies
showed that T1 had potent in vivo activity in inhibiting the growth
of prostate [33] and lung tumors [46]. Although the blood T1
levels were not determined, it would be expected to be below the
in vitro IC50 levels. We hypothesize that the optimal growth
conditions employed in the in vitro studies with carefully
controlled media conditions, temperature and oxygenation may
not be predictive of the complex and harsh in vivo conditions in
the tumor microenvironment, in which hypoxia, necrosis, and
suboptimal perfusion and diffusion limit nutrient availability and
removal of metabolic waste. It is thus imperative to apply clinically
relevant animal models to verify the efficacy of tanshinone
treatment at safe doses.
In conclusion, our study provided at the first time, to the best of
our knowledge, the supporting evidence to suggest that T1 have
potent anti-breast cancer activity in part via downregulation of
Aurora A expression and function. Our results also suggest further
research in developing tanshinones and their derivatives as novel
Aurora A-targeting drug candidates. Moreover, our results
warrant further investigation to evaluate the effect of T1 on
TNBC. Together with our previous findings that T1 also had
potent anti-angiogenesis activity and minimal side effects in vivo,
our studies provide strong evidence to support further investiga-
tions on developing T1 as effective and safe agent for the therapy
and prevention of breast cancer.
Materials and Methods
Ethics Statement
Breast tumors and breast tissues adjacent to tumors from breast
cancer patients and normal breast tissues from healthy women
were purchased from Cooperative Human Tissue Network
(Philadelphia, PA). The protocol was reviewed and approved by
the Committee on Clinical Investigation at Beth Israel Deaconess
Medical Center.
Materials
Tanshinones (CT, T2A and T1) were purchased from LKT (St.
Paul, MN), and the purity was verified by high performance liquid
chromatography. Tissue culture media, fetal bovine serum (FBS),
and trypsin were purchased from Life Technologies, Inc. (Grand
Island, NY). 59-Azacytidin (5-AZA), Sodium butyrate (SB) and
Propidium iodide (PI) were from Sigma (St. Louis, MO). RNase A
and 3-(4,5-dimethyl-thiazol-2yl)-5-(3-carboxymethoxyphenyl) -2-
(4-sulfophenyl)-2H-tetrazolium (MTS) were from Promega (Ma-
dison, WI).
The antibodies used in this study were: cyclin B1 (Oncogene
Research Products, Boston, MA), Bcl-2 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), c-PARP, bax, cyclin D, CDK4, cdc2, p-
cdc2, Aurora kinase A and survivin (Cell Signaling, Beverly, CA)
and b-actin (Merck Co., Darmstadt, Germany).
Cell Lines and Human Tissues
Human breast cancer cell lines (MCF-7, MDA-MB231,
SKBR3, MDA-MB453) were obtained from American Type
Culture Collection and maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% (v/v) heat-inactivated
FBS and antibiotics. All cells were maintained at 37
oCi n
a humidified atmosphere of 95% air and 5% CO2. Human
mammary epithelial cells (HMEC) were obtained from Lonza
(Walkersville, MD) and cultured in mammary epithelium basal
medium (MEBM) plus MEGM single quotes (Lonza) at 37
oCi n
a humidified atmosphere of 95% air and 5% CO2.
Cell Growth Assay
The effects of Tanshinones on cell growth were determined by
using Cell Titer 96 Aqueous One Solution Reagent, MTS
(Promega) as described previously [47]. Briefly, MCF-7 (6000),
MDA-MB231 (3000), SKBR3 (7000), or MDA-MB453 (8000)
cells were plated in each well of 96-well plate and allowed to attach
overnight. Cells were then treated with tanshinones at desired
concentrations or dimethyl sulfoxide (DMSO) as the vehicle and
incubated for 72 hours. MTS was added and incubated for 2 to
4 hours at 37
oCi n5 %C O 2 and light absorbance of formazan was
measured at 490 nm in a microplate reader (VersaMax, Molecular
Device, Sunnyvale, CA). The experiments were independently
performed at least three times, each in triplicates. The results were
confirmed by direct cell counting using a hemocytometer.
Cell Cycle Analysis and DNA Fragmentation
Cell cycle distribution and DNA fragmentation as a marker of
apoptosis in MCF-7 and MDA-MB231 cells were determined by
flow cytometry following the described procedures (Becton
Dickinson, Immunocytometry Systems, Mountview, CA) for cell
cycle distribution using programs provided by Becton Dickinson.
Briefly, cells (MCF-7 and MDA-MB231) were treated with T1 at
desired concentrations for 48 hours, collected, fixed and then
stained with 50mg/ml PI (together with 50mg/ml RNase A).
Stained cells were analyzed by using FACScans (Becton
Dickinson, Mountview, CA) for fragmented DNA and cell cycle
using programs provided by Becton Dickinson. The Sub-G0
proportion represented DNA fragmentation and was considered as
a parameter of apoptosis. The experiment was independently
performed repeated at least once, each in duplicates.
Annexin V and PI Staining for Apoptosis Detection
The effect of Aurora A silencing on the apoptosis-induction
activity of T1 was determined by Annexin V-PI apoptosis
detection kit (Chemicon International Inc, Billerica, MA) following
the instruction of kit. Briefly, treated MCF-7 cells were
resuspended in Annexin V solution and incubated at room
temperature for 15 min, PI was then added for another 5-min
incubation in the dark. Apoptotic cells were analyzed by flow
cytometry (Becton Dickinson, Immunocytometry Systems, Mount-
view, CA). The experiments were independently performed at
least twice, each in duplicates.
Quantitative Real Time Reverse Transcription-PCR
Total RNA was isolated by using Qiagen RNeasy Mini Kit
(Qiagen, Valencia, CA). First-strand cDNA synthesis used 100ng
random primer (Invitrogen, Carlsbad, CA), 1.0mg of total RNA,
10mM dNTP and 200 units of reverse transcriptase (Invitrogen,
Carlsbad, CA) per 20ml reaction. The sequences of primers used in
this study were listed in Table S1. PCRs were performed in a 25ml
final volume by using SYBR Green master mix from SABios-
ciences (SABiosciences, Frederick, MD). Relative mRNA expres-
sion was calculated by the DDCt comparative methods using b-
actin as an internal control.
Aurora A Silencing by siRNA
The Aurora A silencing by siRNA followed the method
described by Lentini and coworkers [23] with appropriate
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4 MCF-7 cells were seeded in a 6 well
plate and incubated for 24h. The silencer negative control and
siRNA for Aurora A (Ambion, Austin, TX) were diluted in Opti-
MEM I Reduced Serum Medium (Invitrogen, Carlsbad, CA) and
transfected with Lipofectamine 2000 according to the manufac-
turer’s instructions. The final concentration of siRNA added to the
cells was 33 nM. The duplex siRNA sequence for Aurora A was as
follows: 59-AUGCCCUGUCUUACUGUCATT-39.
Sodium Bisulfite Treatment of DNA and Methylation
Specific PCR (MSP) Analysis
The DNA promoter methylation status of specific gene was
calculated by using sodium bisulfite treatment of DNA and
methylation specific PCR (MSP) analysis [48]. Briefly, DNA was
extracted by using DNeasy Blood & Tissue Kit (Qiagen, Valencia,
CA). 2mg genomic DNA was diluted in 20mL water and subjected
to bisulfite DNA conversion according to the protocols provided in
the Epitect Bisulfite Kit (Qiagen, Valencia, CA). The converted
DNA was then purified for MSP analysis by using PCR
amplifications. A typical reaction consisted of 2.5 mL of 10X
standard PCR buffer, 0.4 mL1 0mM dNTP, 2.5 U platinum Taq
DNA polymerase (Invitrogen), 25 pmol of each methylated or
unmethylated DNA-specific primers, and ultrapure DNAse-/
RNAse-free water in a total volume of 25 mL. PCR products will
be resolved on non-denaturing polyacrylamide gels, stained with
ethidium bromide, and visualized under UV illumination.
Chromatin Immunoprecipitation (CHIP)
The experiment was performed according to the description of
the Magna ChIP
TM& EZ-Magna ChIP
TM Kit (Millipore, Bill-
erica, MA). In brief, cells were fixed by formaldehyde and
harvested. The cells were then broken open for nuclear extraction
and the DNA was sheared to 200–1000bp fragments by
sonication. The sonicated DNA was used for immunoprecipitation
by using anti-acetyl histone antibody. The immunoselected DNA
was further purified and analyzed by quantitative real-time PCR
using specific primers of Aurora A (Table S1). Q-PCR values were
normalized to input and enrichment compared to IgG control
samples.
Western Blot Analysis
Cells were treated with different concentrations of tanshinones,
cell lysates were prepared, and protein expression was determined
following the procedures we previously described [47,49]. The
protein levels were quantitated by using densitometric analysis by
using NIH image analysis software and expressed as percentages of
the control after being normalized with the housekeeping protein
of b-actin. The primary antibodies used were Aurora A (1:1000),
bcl-2 (1:200), cyclin B (1:1000), cdc2 (1:1000), CDK4 (1:1000),
cyclin D (1:1000), c-PARP (1:1000), p-cdc2 (1:1000), survivin
(1:1000) and b-actin (1:10,000).
Statistical Analysis
Results were expressed as group means6SEM and analyzed for
statistical significance by analysis of variance followed by Fisher’s
protected least-significant difference based on two-side compar-
isons among experimental groups by using Statview 5.0 program
(SAS Institute, Inc., Cary, NC). A P , 0.05 was considered
statistically significant.
Supporting Information
Figure S1 Representative FACS histograms showing the
effects of T1 treatments (3 and 4mM) on cell cycle
progression in MCF-7 (A-C) and MDA-MB231 (D-F) cell
lines.
(TIF)
Figure S2 Effects of T1 treatment (4mM) on Aurora A
gene expression in MCF-7 cells. Values were mean6SEM of
three independent experiments in triplicates. The value with
a letter is significantly different from that of the corresponding
control (c, p,0.001).
(TIF)
Figure S3 The representative image showing unmethy-
lation status of Aurora A gene DNA promoter in MCF-7,
MDA-MB231, SKBR3 and MDA-MB453 human breast
cancer cell lines, as determined by methylation specific
PCR (MSP).
(TIF)
Table S1 Sequences of the primers.
(DOC)
Table S2 Raw Ct values for Figure 7 A, B, and C.
(DOC)
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